From hormone-replacement therapies to super-effective breast-cancer drugs to the so-called female Viagra, innovation within the women's health category has accelerated in recent months.
While advances in the treatment of hep.-C have been well noted, the infectious-diseases space has seen considerably less innovation than many other therapeutic areas. Given the stubbornness of superbugs like MRSA and growing antibiotic resistance, the healthcare industry has finally turned its attention to the category. Rebecca Mayer Knutsen outlines the potential threats and solutions
The respiratory field, in which several launches are under way, is branching out, from long-time dominant fixed-dose combinations to a therapeutic arsenal that includes biologics and gene therapy. Rebecca Mayer Knutsen investigates the innovation and the intrigue
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.